Approach: Developing antigen-specific immune tolerance therapies for autoimmune and allergic diseases
Strategic Area: Immunotherapies
T1D Funding Impact: Catalyzing company formation and T1D program, together with a pharmaceutical company partner
Member count: 11-50
Total raised: $4M
Founded date: 2014
Investors 1
| Date | Name | Website |
| - | T1D Fund | t1dfund.or... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 08.09.2016 | Series A | $4M | - | finsmes.co... |
Mentions in press and media 2
| Date | Title | Description | Category | Author | Source |
| 08.09.2016 | Pfizer se... | Pfizer is backing a newly m... | - | John Carro... | endpts.com... |
| 08.09.2016 | AnTolRx Cl... | AnTolRx, Inc., a Cambridge, Ma... | USA | - | finsmes.co... |